Epsilen Bio Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
4
- Latest Deal Type
-
M&A
Epsilen Bio General Information
Description
Operator of a biotechnological platform intended to provide genomic epigenetic silencing of genes involved in pathological processes. The company's platform specializes in developing transformative therapies for patients affected by underserved medical conditions through stable genomic epigenetic silencing of genes involved in pathological processes, enabling healthcare professionals to access new therapies.
Contact Information
Website
www.epsilenbio.comCorporate Office
- Via Vincenzo Gioberti, 8
- 20123 Milan
- Italy
Corporate Office
- Via Vincenzo Gioberti, 8
- 20123 Milan
- Italy
Epsilen Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 17-Nov-2021 | Completed | Startup | |||
| 1. Seed Round | 20-Apr-2020 | Completed | Startup |
Epsilen Bio Comparisons
Industry
Financing
Details
Epsilen Bio Competitors (2)
One of Epsilen Bio’s 2 competitors is Genespire, a Venture Capital-Backed company based in Milan, Italy.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genespire | Venture Capital-Backed | Milan, Italy | ||||
| Altheia Science | Venture Capital-Backed | Milan, Italy |
Epsilen Bio Patents
Epsilen Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12649003-B2 | Compositions and methods for epigenetic regulation of hbv gene expression | Active | 15-May-2023 | ||
| US-20250288691-A1 | Compositions and methods for epigenetic regulation of hbv gene expression | Active | 15-May-2023 | ||
| AU-2022213505-A1 | Gene silencing | Pending | 01-Feb-2021 | ||
| CA-3207166-A1 | Gene silencing | Pending | 01-Feb-2021 | ||
| EP-4284932-A1 | Gene silencing | Pending | 01-Feb-2021 | A61K40/31 |
Epsilen Bio Signals
Epsilen Bio Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sofinnova Partners | Venture Capital | Minority |
Epsilen Bio FAQs
-
When was Epsilen Bio founded?
Epsilen Bio was founded in 2019.
-
Where is Epsilen Bio headquartered?
Epsilen Bio is headquartered in Milan, Italy.
-
What is the size of Epsilen Bio?
Epsilen Bio has 4 total employees.
-
What industry is Epsilen Bio in?
Epsilen Bio’s primary industry is Drug Discovery.
-
Is Epsilen Bio a private or public company?
Epsilen Bio is a Private company.
-
What is Epsilen Bio’s current revenue?
The current revenue for Epsilen Bio is .
-
How much funding has Epsilen Bio raised over time?
Epsilen Bio has raised $2.51M.
-
Who are Epsilen Bio’s investors?
Sofinnova Partners has invested in Epsilen Bio.
-
Who are Epsilen Bio’s competitors?
Genespire and Altheia Science are competitors of Epsilen Bio.
-
When was Epsilen Bio acquired?
Epsilen Bio was acquired on 17-Nov-2021.
-
Who acquired Epsilen Bio?
Epsilen Bio was acquired by Chroma Medicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process